China Contract Research Organization (CRO) Industry Report, 2010-2011
  • July/2011
  • Hard Copy
  • USD $1,800
  • Pages:58
  • Single User License
    (PDF Unprintable)       
  • USD $1,700
  • Code: HM003
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,500
  • Hard Copy + Single User License
  • USD $2,000
Under the circumstances of increasingly high R&D costs of new drugs worldwide, the contract research organization (CRO) industry has developed rapidly in recent years thanks to its advantages of shortening the R&D cycle and cost saving. In 2010, the global market size of CRO achieved RMB36 billion, which undertook nearly one third of the R&D of new drugs. CRO industry started relatively late in China, and still in its initial stage with only a few business varieties. In China, the market size of CRO was merely USD2.6 billion (about RMB16.9 billion) in 2010. However, with rapid development, currently there are almost 500 CRO enterprises in China.

Although there are many CRO enterprises in China, large-scale enterprises are less than 10 companies. WuXi AppTec and ShangPharma, two NYSE listed companies, are the largest CRO enterprises in China. WuXi AppTec is the leading enterprise in domestic CRO industry, whose clients include 9 of the top 10 pharmaceutical enterprises worldwide. In Jan. 2008, it successfully acquired AppTec Laboratory Services Inc. for USD151 million, initiating the overseas expansion of Chinese CRO enterprises.

ShangPharma is the second largest CRO enterprise in China. It has over 100 enterprise and academic research institution clients, including the top 10 pharmaceutical enterprises in the world. With the aim to enhance its R&D strength, ShangPharma plans to construct cGMP base and laboratory service building with the funds raised from its IPO in 2010.

Currently, most of the CRO enterprises can only accomplish a single section in the R&D process, therefore, in order to complete the industry chain and enhance the competitiveness, M&A and setting up industry alliance has become a trend in China’s CRO industry. From 2007 to Apr. 2011, there were at least 6 M&A cases in the CRO industry of China. As of Apr. 2011, there were five biopharmaceutical CRO industry alliances in China, including Alliance of Bio-Box Outsourcing, China, Zhongguancun Bio-pharmaceutical R&D Outsourcing Alliance, Shanghai Pudong Bio-Pharmaceutical R&D Outsourcing Service Alliance, CROSA and Chengdu Bio-pharmaceutical R&D Outsourcing Alliance. Having witnessed the advantage of CRO alliances in China, foreign companies participated in as well. For instance, the European company NovaSecta joined CROSA.  

M&A Cases of CRO Industry in China, 2007-2011
Source: ResearchInChina
1.Overview of CRO Industry 
1.1 Definition & Classification
1.2 Industry Background

2. Development Environment of CRO Industry in China
2.1 International Environment
2.2 Industry Environment
2.3 Policy Environment

3. Market Analysis of CRO Industry in China
3.1 Status Quo
3.2 Market Size
3.3 Competition Pattern
3.4 Prospects
3.4.1 Specialized Division of Labor 
3.4.2 Low Entry Barriers
3.4.3 Huge Demand
3.5 CRO Industry Alliances in China
3.5.1 ABO
3.5.2 Zhongguancun Bio-pharmaceutical R&D Outsourcing Alliance
3.5.3 Shanghai Pudong Bio-Pharmaceutical R&D Outsourcing Service Alliance 
3.5.4 CROSA
3.5.5 Chengdu Bio-pharmaceutical R&D Outsourcing Alliance 

4. Regional Market
4.1 Beijing
4.1.1 Pharmaceutical Manufacturing with Steady Growth
4.1.2 G20 Enterprises have Become the Core Strength of Industrial Development
4.1.3 R&D Services Industry Presents Prominent Contribution, with ABO Union Becoming an Important Force.
4.2 Shanghai
4.2.1 State Biotech & Pharmaceutical Industrial Base (Shanghai) (Zhangjiang Drug Valley)
4.3 Nanjing
4.3.1 Market Advantage 
4.3.2 Development Prospects

5. Key CRO Enterprises Worldwide
5.1.1 Profile
5.1.2 Operation
5.1.3 Business in China
5.2.1 Profile
5.2.2 Business in China
5.3 PPD
5.3.1 Profile
5.3.2 Business in China
5.4 Quintiles Transnational
5.4.1 Profile
5.4.2 Business in China
5.5 Charles River Labs (CRL)
5.5.1 Profile
5.5.2 Business in China
5.6 Asymchem Inc
5.6.1 Profile
5.6.2 Asymchem Laboratories (Tianjin) Co. Ltd. 
5.6.3 Asymchem Life Science (Tianjin) Co., Ltd.
5.7 MDS Inc.
5.7.1 Profile
5.7.2 MDS Pharma Services (China) Inc.

6.Key CRO Enterprises in China
6.1 WuXi AppTec Co., Ltd.
6.1.1 Profile
6.1.2 Operation
6.1.3 Business Structure
6.1.4 Development
6.2 ShangPharma Corp
6.2.1 Profile
6.2.2 Operation
6.2.3 Development
6.2.4 Shanghai ChemPartner Co. Ltd
6.2.5 Shanghai ChemExplorer Co. Ltd
6.2.6 Chengdu China Gateway Pharmaceutical Development Co. Ltd
6.3 Venturepharm Laboratories Limited
6.3.1 Profile
6.3.2 Operation
6.3.3 Development
6.4 Sundia MediTech Co., Ltd
6.5 Chemizon (Beijing) Pharma-Tech Co., Ltd
6.6 Excel PharmaStudies Co. Ltd
6.7 Tigermed Pharma-Tech Co., Ltd
Classification of CRO
Market Size and Growth Rate of Global CRO, 2007-2010
Global Key CRO Organizations and Their Business 
Industrial Sales Output Value and Growth Rate of Pharmaceutical Manufacturing Industry in China, 2008-Apr. 2011
Output Value of New Products of Pharmaceutical Manufacturing Industry in China, 2008-2010 
Classification of Chinese CRO Companies (by Business)
Market Size and Growth Rate of CRO in China, 2007-2010
Key M&A Cases of CRO Industry in China, 2007-2011
Orders and Revenue of ABO Union and Proportions in International Orders ,2008-2010
Key Members and Unique Services of ABO Union
Sponsor of Zhongguancun CRO Union (in no particular order)
Biopharmaceutical CRO Companies in Shanghai Pudong New Area
CRO Service Chain of Shanghai Pudong Zhangjiang 
Operating Income and Total Profit of Beijing Pharmaceutical Industry by Sector, 2010
Advantageous Fields of Beijing CRO Services
Platform Edge of Zhangjiang Drug Valley 
List of Major CRO Companies of Zhangjiang Drug Valley, Shanghai 
Industry Advantages of CRO Nanjing 
Operating Income and Gross Margin of Covance, 2007-2010
Operating Income of Covance (by Business), 2008-2010
Operating Income of PAREXEL, 2007-2010
Revenue of PAREXEL Worldwide (by Region), 2008-2010 
Operating Income of PPD, 2007-2010
Sales of CRL, 2007-2010
Companies of Asymchem Inc in China and Major Business
Operation of Asymchem Laboratories (Tianjin), 2008 and Jan. 2009- May 2009
Operation of Asymchem Life Science (Tianjin), 2008 
Major Facilities of WuXi AppTec
Sales and Gross Margin of WuXi AppTec, 2008-2010
Sales of WuXi AppTec (By Business), 2010
Main Bases of ShangPharma Corp
Net Income and Gross Profit of ShangPharma Corp, 2008-2010
Net Income of ShangPharma Corp Worldwide (by Region), 2007-2009
Revenue and Gross Profit of Venturepharm Laboratories Limited, 2007- Jan.- Mar.2011
Operation of Venturepharm Laboratories Limited, 2007-Jan.- Mar.2011
Patents Applied by Venturepharm Laboratories Limited
Strength of Excel PharmaStudies
Main Clients of Tigermed Pharma-Tech

China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号